Continuing Education Home Study Package
Below are the four articles included in your continuing education home study package. For each title, read the complete article associated with it and then complete the evaluation and posttest by clicking on "Begin Activity" in the right sidebar. NOTE: The evaluation and posttest is a compilation of all four articles. Be sure to read all the articles before beginning the evaluation and posttest as you will not be able to go back once you begin.
This continuing education activity was designed specifically for pharmacists.
Article 1: Prescription Drug Abuse and Prevention
At the end of this activity, participants should be able to define physical and psychological dependence; explain the methods by which pharmacy professionals can impact rates of drug abuse and diversion; and explain the role of corresponding responsibility in pharmacy practice.
Katie Wenstrom, Pharm.D., staff/clinical pharmacist, Meijer, and residency coordinator, Meijer/Pfizer/Ferris State University (FSU); and Brooke McComb, Pharm.D., pharmacist, Meijer
At the end of this activity, participants should be able to describe the value of rapid diagnostic testing (RDT) to patient care; identify some of the current tests available by pharmacy-based RDT; explain how to overcome obstacles associated with RDT; and recognize proper procedures for implementation of RDT.
Brooke McComb, Pharm.D., pharmacist, Meijer
Article 3: Speaking to Patients About Medication Adherence
At the end of this activity, participants should be able to define medication adherence and adherence rates; explain how community pharmacies measure medication adherence; identify barriers to nonadherence for the patient and for pharmacists; and discuss communication strategies that pharmacists can use to increase adherence among the nonadherent patient population.
Kathryn Dudzinski, Pharm.D., Postgraduate Year 1 pharmacy resident, Meijer/Pfizer/Ferris State University College of Pharmacy
Article 4: The Future Impact of USP 800 in the Health Care Setting
At the end of this activity, participants should be able to state the definition of a hazardous drug; identify drugs which are hazardous in nature; identify potential health risks associated with exposure to hazardous drugs; recognize differences between required engineering controls for nonsterile and sterile hazardous drug compounding and explain how to create a medical surveillance program within a health system.
Ashley Tocco, Pharm.D., BCPS, lead IV room pharmacist, Bronson Methodist Hospital
Continuing Education Credit
Michigan Pharmacists Association (MPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Universal Activity #0112-0000-16-003-H04-P; 4.5 contact hours; Initial Release Date: 6/15/16; Expiration Date: 6/15/19
The authors have indicated that they do not have any conflicts of interest, nor do they have financial relationships with a commercial interest, related to this activity.
To adequately view continuing education articles, please visit the Adobe Web site for the latest technical specifications for your version of Adobe Reader.
To adequately view continuing education articles, you must have Adobe Reader 6.0+. To download the latest version based on your operating system, please visit the Adobe Web site.
To adequately view articles, you must have at least a Broadband Internet connection with 500+ Kbps.
For questions regarding continuing education, please contact MPA Director of Continuing Education, Mary Farrington, at Mary@MichiganPharmacists.org or at (517) 377-0234.